

**Chemiluminescence Immunoassay Market by Product (Instrument, Consumable), Technology (Chemiluminescence Enzyme, Microparticle Chemiluminescence), Sample (Blood, Urine), Application (Infectious Disease, Oncology), End User - Global Forecast to 2028**

Market Report | 2023-07-05 | 276 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The chemiluminescence immunoassay market is valued at an estimated USD 13.2 billion in 2023 and is projected to reach USD 19.0 billion by 2028 at a CAGR of 7.5% during the forecast period. Diseases such as HIV/AIDS, hepatitis, respiratory infections and sexually transmitted infections, require an accurate and timely diagnosis for effective treatment and control. Chemiluminescence immunoassay plays a major role in the diagnosis and monitoring of these infectious diseases, driving the growth of the market in this area.

"Blood samples segment is projected to witness highest growth rate in the chemiluminescence immunoassay market, by sample type, during the forecast period"

The chemiluminescence immunoassay market is segmented into blood, urine, saliva, and other sample types. The blood segment in chemiluminescence immunoassay is experiencing significant growth, primarily driven by the increasing number of blood donations and the rising incidence of chronic and infectious diseases also support the growth of the blood samples segment. According to the WHO, in 2020, over 118.5 million blood donations were collected worldwide. The WHO recommends testing all donated blood for infections before use, especially syphilis, HIV, malaria, HBV, and hepatitis B and C.

"Oncology testing segment is projected to register highest growth rate in the chemiluminescence immunoassay market, by application, during the forecast period"

The global chemiluminescence immunoassay market is bifurcated into infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening,

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

therapeutic drug monitoring, respiratory, neurology, metabolic disorders, gastroenterology, and other applications. Oncology testing segment is expected to grow at the highest rate within the chemiluminescence immunoassay market. The surge in demand for oncology testing is attributed to various factors such as rise in the incidence of cancer, increasing emphasis on the need for early detection and treatment of cancer, along with measures to increase cancer screening measures.

"Asia Pacific: The fastest-growing region chemiluminescence immunoassay market"

The global chemiluminescence immunoassay market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period.

Emerging countries in Asia Pacific such as China and India have been investing in developing their healthcare infrastructure, coupled with the presence of large target population. These factors are expected to provide significant growth opportunities for chemiluminescence immunoassay companies operating in this region.

The break-up of the profile of primary participants in the chemiluminescence immunoassay market:

-□By Company Type: Tier 1 - 28%, Tier 2 - 41%, and Tier 3 - 31%

-□By Designation: C-level - 30%, D-level - 34%, and Others - 36%

-□By Region: North America - 37%, Europe - 28%, Asia Pacific - 20%, Rest of the World- 15%

The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (US), Shenzhen Mindray Bio-medical Electronics Co., Ltd. (China), Sysmex Corporation (Japan), Diatron (Hungary), GeteIn Biotech, Inc. (China), Werfen (Spain), QuidelOrtho Corporation (US), EUROIMMUN (Germany), Merck KGaA (Germany), Tosoh Corporation (Japan), Trivitron Healthcare (India), Abnova Corporation (Taiwan), Elabscience (US), Maccura Biotechnology Co., Ltd. (China), Autobio Diagnostics Co., Ltd. (China), Jiangsu Zecen Biotech Co., Ltd (China), Rayto Life and Analytical Sciences Co., Ltd. (China), Daan Gene Co., Ltd. (China), DYNEX TECHNOLOGIES, Inc. (US), Zybion, Inc. (China), Wiener Laboratorios SAIC (Argentina), Tianjin Era Biology Technology Co., Ltd. (China).

Research Coverage:

This research report categorizes the chemiluminescence immunoassay market by product (consumables and instruments), technology (Chemiluminescence Enzyme Technology (CLEIA), Electrochemiluminescence immunoassay (ECL), and Microparticle Chemiluminescence Immunoassay), sample type (blood, urine, saliva, and other sample types), application (infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, therapeutic drug monitoring, respiratory, neurology, metabolic disorders, gastroenterology, and other applications), end user (hospitals, clinical laboratories, pharmaceuticals & biotechnology companies and contract research organizations, and other end users), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the chemiluminescence immunoassay market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements, new product launches and approvals, and recent developments associated with the chemiluminescence immunoassay market. Competitive analysis of upcoming startups in the chemiluminescence immunoassay market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall chemiluminescence immunoassay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

-□Analysis of key drivers (increasing incidences of chronic and infectious diseases, advances in improving the CLIA technologies, rising demand for point-of-care testing (POCT), growth of biotechnology and biopharmaceutical industries, growing geriatric population, and shift towards personalized medicine), restraints (high cost of CLIA systems and reagents and cross-reactivity and

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

interference), opportunities (high growth prospects in emerging countries and collaborations and partnerships), and challenges (unfavorable reimbursement scenario and lack of skilled professionals) influencing the growth of the chemiluminescence immunoassay market

- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the chemiluminescence immunoassay market.

- Market Development: Comprehensive information about lucrative markets - the report analyses the chemiluminescence immunoassay market across varied regions.

- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the chemiluminescence immunoassay market

- Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Seimens Healthineers AG (Germany), Abbott Laboratories (US), and DiaSorin S.p.A.(Italy), among others in the chemiluminescence immunoassay market strategies.

## Table of Contents:

1□INTRODUCTION□	31
1.1□STUDY OBJECTIVES□	31
1.2□MARKET DEFINITION□	31
1.2.1□INCLUSIONS AND EXCLUSIONS□	32
1.3□MARKET SCOPE□	33
1.3.1□MARKETS COVERED□	33
FIGURE 1□CHEMILUMINESCENCE IMMUNOASSAY MARKET SEGMENTATION□	33
1.3.2□GEOGRAPHICAL SCOPE□	33
1.3.3□YEARS CONSIDERED□	34
1.4□CURRENCY CONSIDERED□	34
1.5□STAKEHOLDERS□	35
2□RESEARCH METHODOLOGY□	36
2.1□RESEARCH APPROACH□	36
FIGURE 2□RESEARCH DESIGN□	36
2.1.1□SECONDARY DATA□	37
2.1.1.1□Key data from secondary sources□	38
2.1.2□PRIMARY DATA□	38
2.1.2.1□Primary sources□	39
2.1.2.2□Key data from primary sources□	40
2.1.2.3□Key industry insights□	41
FIGURE 3□BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND SIDE PARTICIPANTS□	41
FIGURE 4□BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION□	42
2.2□MARKET SIZE ESTIMATION□	42
FIGURE 5□REVENUE SHARE ANALYSIS ILLUSTRATION□	43
FIGURE 6□MARKET ESTIMATION FROM IVD MARKET□	44
FIGURE 7□MARKET ESTIMATION FROM IMMUNOASSAY MARKET□	44
FIGURE 8□CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY MARKET□	45
FIGURE 9□TOP-DOWN APPROACH□	45
2.3□MARKET BREAKDOWN AND DATA TRIANGULATION□	47
FIGURE 10□DATA TRIANGULATION METHODOLOGY□	47
2.4□MARKET SHARE ANALYSIS□	48
2.5□STUDY ASSUMPTIONS□	48
2.6□RESEARCH LIMITATIONS□	48

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## 2.7 RISK ASSESSMENT 49

### TABLE 1 RISK ASSESSMENT: CHEMILUMINESCENCE IMMUNOASSAY MARKET 49

## 2.8 GROWTH RATE ASSUMPTIONS 49

### 2.9 IMPACT OF RECESSION ON CHEMILUMINESCENCE IMMUNOASSAY MARKET 49

## 3 EXECUTIVE SUMMARY 51

### FIGURE 11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION) 51

### FIGURE 12 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION) 52

### FIGURE 13 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD BILLION) 53

### FIGURE 14 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION) 54

### FIGURE 15 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 55

### FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CHEMILUMINESCENCE IMMUNOASSAY MARKET 56

## 4 PREMIUM INSIGHTS 57

### 4.1 CHEMILUMINESCENCE IMMUNOASSAY MARKET OVERVIEW 57

#### FIGURE 17 INCREASING INCIDENCE OF DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 57

### 4.2 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT (2022) 58

#### FIGURE 18 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 58

### 4.3 GEOGRAPHICAL GROWTH OPPORTUNITIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 59

#### FIGURE 19 CHINA AND INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 59

### 4.4 CHEMILUMINESCENCE IMMUNOASSAY MARKET: REGIONAL MIX 60

#### FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD 60

### 4.5 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS 61

#### FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING STUDY PERIOD 61

## 5 MARKET OVERVIEW 62

### 5.1 INTRODUCTION 62

### 5.2 MARKET DYNAMICS 62

#### FIGURE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62

#### 5.2.1 DRIVERS 63

##### 5.2.1.1 Increasing incidences of chronic and infectious diseases globally 63

#### FIGURE 23 INCREASING INCIDENCES OF DIABETES (GLOBAL) 63

#### FIGURE 24 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 1995-2030 (MILLION INDIVIDUALS) 64

##### 5.2.1.2 Advancements in improving chemiluminescence immunoassay technologies in recent years 64

##### 5.2.1.3 Growth of biotechnology and biopharmaceutical industries 66

##### 5.2.1.4 Rapid increase in geriatric population globally 67

#### FIGURE 25 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION) 67

##### 5.2.1.5 Shift toward personalized medicines and individualized treatment decisions 68

#### 5.2.2 RESTRAINTS 68

##### 5.2.2.1 High cost of chemiluminescence systems and reagents 68

##### 5.2.2.2 Lack of regular quality control procedures for monitoring and detecting cross-reactivity and interference 68

#### 5.2.3 OPPORTUNITIES 69

##### 5.2.3.1 High growth prospects for players in emerging economies 69

##### 5.2.3.2 Increasing number of collaborations and partnerships 70

#### 5.2.4 CHALLENGES 70

##### 5.2.4.1 Unfavorable reimbursement scenario and budgetary constraints in healthcare systems 70

##### 5.2.4.2 Lack of skilled professionals and aging workforce 70

## 5.3 VALUE CHAIN ANALYSIS 71

#### FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 71

## 5.4 SUPPLY CHAIN ANALYSIS 72

FIGURE 27□DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES□72

5.5□PORTER'S FIVE FORCES ANALYSIS□73

TABLE 2□HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS□73

5.5.1□DEGREE OF COMPETITION□73

5.5.2□BARGAINING POWER OF SUPPLIERS□73

5.5.3□BARGAINING POWER OF BUYERS□73

5.5.4□THREAT OF SUBSTITUTES□73

5.5.5□THREAT OF NEW ENTRANTS□74

5.6□KEY STAKEHOLDERS AND BUYING CRITERIA□74

5.6.1□KEY STAKEHOLDERS IN BUYING PROCESS□74

FIGURE 28□INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS□74

TABLE 3□INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS□74

5.6.2□BUYING CRITERIA□75

FIGURE 29□KEY BUYING CRITERIA FOR MAJOR END USERS□75

TABLE 4□KEY BUYING CRITERIA, BY END USER□75

5.7□REGULATORY LANDSCAPE□76

5.7.1□US□76

TABLE 5□US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS□76

FIGURE 30□US: REGULATORY PROCESS FOR IVD DEVICES□77

5.7.2□CANADA□78

FIGURE 31□CANADA: REGULATORY PROCESS FOR IVD DEVICES□78

5.7.3□EUROPE□78

TABLE 6□EUROPE: CLASSIFICATION OF IVD DEVICES□78

5.7.4□JAPAN□79

FIGURE 32□JAPAN: REGULATORY PROCESS FOR IVD DEVICES□79

TABLE 7□JAPAN: CLASSIFICATION OF IVD REAGENTS□80

TABLE 8□JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS□80

5.7.5□CHINA□80

TABLE 9□CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS□80

5.7.6□INDIA□81

FIGURE 33□INDIA: REGULATORY PROCESS FOR IVD DEVICES□81

5.7.7□INDONESIA□81

TABLE 10□INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES□82

5.7.8□RUSSIA□82

TABLE 11□RUSSIA: CLASSIFICATION OF IVD DEVICES□82

5.7.9□SAUDI ARABIA□83

TABLE 12□SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS□83

5.7.10□MEXICO□83

FIGURE 34□MEXICO: REGULATORY PROCESS FOR IVD DEVICES□83

TABLE 13□MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS□84

5.7.11□BRAZIL□84

FIGURE 35□BRAZIL: REGULATORY PROCESS FOR IVD DEVICES□85

5.7.12□SOUTH KOREA□85

TABLE 14□SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS□85

5.7.13□MIDDLE EAST□85

5.7.14□AFRICA□86

5.8□TECHNOLOGY ANALYSIS□86

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 15	RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET	86
5.9	TRADE ANALYSIS	87
5.9.1	TRADE ANALYSIS FOR CHEMILUMINESCENCE IMMUNOASSAYS	87
TABLE 16	IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018-2022 (USD MILLION)	87
TABLE 17	EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018-2022 (USD MILLION)	87
5.10	ECOSYSTEM MAPPING	88
FIGURE 36	ECOSYSTEM MAPPING OF CHEMILUMINESCENCE IMMUNOASSAY MARKET	88
5.10.1	ROLE IN ECOSYSTEM	88
5.10.2	KEY PLAYERS OPERATING IN CHEMILUMINESCENCE IMMUNOASSAY MARKET	89
5.11	PATENT ANALYSIS	89
5.12	KEY CONFERENCES AND EVENTS IN 2023-2024	90
TABLE 18	LIST OF CONFERENCES AND EVENTS IN 2023-2024	90
5.13	PRICING ANALYSIS	91
5.13.1	AVERAGE SELLING PRICE, BY APPLICATION (KEY PLAYERS)	91
TABLE 19	PRICE RANGE OFFERED BY KEY PLAYERS, BY APPLICATION (USD)	91
5.14	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	91
6	CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT	92
6.1	INTRODUCTION	93
TABLE 20	CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	93
6.2	CONSUMABLES	93
6.2.1	CONSUMABLES TO ACCOUNT FOR LARGEST SHARE OF CHEMILUMINESCENCE IMMUNOASSAY MARKET DURING STUDY PERIOD	93
TABLE 21	LIST OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES AVAILABLE	94
TABLE 22	CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CONSUMABLES, BY REGION, 2021-2028 (USD MILLION)	95
6.3	INSTRUMENTS	95
6.3.1	INCREASING ADVANCES WITH HIGH-THROUGHPUT CAPACITIES AND GROWING AUTOMATION TRENDS TO DRIVE MARKET	95
TABLE 23	LIST OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS AVAILABLE	96
TABLE 24	CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)	97
7	CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY	98
7.1	INTRODUCTION	99
TABLE 25	CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	99
7.2	CHEMILUMINESCENCE ENZYME	99
7.2.1	HIGH RELIABILITY OF BLOOD TESTS IN CLINICAL DIAGNOSTICS AND PHARMACEUTICAL RESEARCH TO DRIVE MARKET	99
TABLE 26	CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CHEMILUMINESCENCE ENZYME, BY REGION, 2021-2028 (USD MILLION)	100
7.3	ELECTROCHEMILUMINESCENCE IMMUNOASSAY	100
7.3.1	INCREASED GENERATION OF EXCITED STATES THROUGH BETTER ELECTRODE VARIATION TO DRIVE MARKET	100
TABLE 27	CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ELECTROCHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021-2028 (USD MILLION)	101
7.4	MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY	101
7.4.1	HIGHER COSTS AND GREATER CHANCES OF CROSS-REACTIVITY DUE TO MULTIPLEXING TO LIMIT MARKET	101
TABLE 28	CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021-2028 (USD MILLION)	102
8	CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE	103
8.1	INTRODUCTION	104
TABLE 29	CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	104
8.2	BLOOD	104

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.2.1	HIGH RELIABILITY OF BLOOD TESTS FOR IMMUNOASSAY DIAGNOSTIC PROCEDURES AND HEALTH SCREENING TO DRIVE MARKET	104
TABLE 30 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD, BY REGION, 2021-2028 (USD MILLION)		
8.3	URINE	105
8.3.1	INCREASING USE IN LAW ENFORCEMENT AND DRUG TESTING CENTERS TO DRIVE MARKET	105
TABLE 31 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR URINE, BY REGION, 2021-2028 (USD MILLION)		
8.4	SALIVA	106
8.4.1	CONVENIENCE AND EASY TESTING OF BIOLOGICALLY ACTIVE PARTS OF HORMONES TO DRIVE MARKET	106
TABLE 32 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR SALIVA, BY REGION, 2021-2028 (USD MILLION)		
8.5	OTHER SAMPLE TYPES	107
TABLE 33 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021-2028 (USD MILLION)		
9	CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION	109
9.1	INTRODUCTION	110
TABLE 34 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)		
9.2	INFECTIOUS DISEASES	111
9.2.1	RIISING PREVALENCE OF INFECTIOUS DISEASES GLOBALLY AMONG ALL AGE GROUPS TO DRIVE MARKET	111
TABLE 35 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)		
9.3	ENDOCRINOLOGY	112
9.3.1	RIISING INCIDENCES OF DIABETES GLOBALLY TO DRIVE MARKET	112
TABLE 36 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ENDOCRINOLOGY, BY REGION, 2021-2028 (USD MILLION)		
9.4	ONCOLOGY	113
9.4.1	RIISING BURDEN OF CANCER AND EMPHASIS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET	113
TABLE 37 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)		
TABLE 38 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)		
9.5	CARDIOLOGY	115
9.5.1	HIGH BURDEN OF CARDIOVASCULAR DISEASES AMONG ALL AGE GROUPS TO DRIVE MARKET	115
TABLE 39 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CARDIOLOGY, BY REGION, 2021-2028 (USD MILLION)		
9.6	ALLERGY DIAGNOSTICS	116
9.6.1	GROWING PREVALENCE OF ALLERGIES TO REGISTER INCREASED DEMAND FOR CHEMILUMINESCENCE IMMUNOASSAYS	116
TABLE 40 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)		
9.7	BLOOD SCREENING	117
9.7.1	RIISING VOLUME OF BLOOD DONATIONS AND INCREASING INCIDENCES OF BLOOD-RELATED DISORDERS TO DRIVE MARKET	117
TABLE 41 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD SCREENING, BY REGION, 2021-2028 (USD MILLION)		
9.8	AUTOIMMUNE DISORDERS	118
9.8.1	GROWING PREVALENCE OF AUTOIMMUNE DISORDERS AND RISING ECONOMIC BURDEN OF DISEASE MANAGEMENT TO DRIVE MARKET	118
TABLE 42 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021-2028 (USD MILLION)		
9.9	BONE & MINERAL DISORDERS	119
9.9.1	HIGH DISORDER PREVALENCE TO INDICATE STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS	119
TABLE 43 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)		
9.10	TOXICOLOGY	120
9.10.1	INCREASED DRUG-OF-ABUSE TESTING AND HIGHER ILLICIT DRUG CONSUMPTION TO DRIVE MARKET	120
TABLE 44 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR TOXICOLOGY, BY REGION, 2021-2028 (USD MILLION)		
9.11	NEWBORN SCREENING	121

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

9.11.1	CHEMILUMINESCENCE IMMUNOASSAYS TO BE ROUTINELY USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL	121
TABLE 45	CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEWBORN SCREENING, BY REGION, 2021-2028 (USD MILLION)	122
9.12	THERAPEUTIC DRUG MONITORING	122
9.12.1	RAPID DETECTION TIME AND GOOD SPECIFICITY TO DRIVE MARKET	122
TABLE 46	CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR THERAPEUTIC DRUG MONITORING, BY REGION, 2021-2028 (USD MILLION)	123
9.13	METABOLIC DISORDERS	123
9.13.1	RISING PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET	123
FIGURE 37	GLOBAL INCIDENCE OF DIABETES	124
TABLE 47	CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021-2028 (USD MILLION)	124
9.14	GASTROENTEROLOGY	125
9.14.1	INCREASING INCIDENCE OF GASTROINTESTINAL TRACT INFECTIONS AND SERIOUS GASTRIC DISEASES TO DRIVE MARKET	125
TABLE 48	CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR GASTROENTEROLOGY, BY REGION, 2021-2028 (USD MILLION)	125
9.15	NEUROLOGY	126
9.15.1	EFFECTIVE DETECTION, MONITORING, AND MANAGEMENT OF NEUROLOGICAL DISORDERS TO DRIVE SEGMENT	126
TABLE 49	CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEUROLOGY, BY REGION, 2021-2028 (USD MILLION)	126
9.16	RESPIRATORY	127
9.16.1	EASY DETECTION AND DIAGNOSIS OF RESPIRATORY DISEASES TO DRIVE MARKET	127
TABLE 50	CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR RESPIRATORY, BY REGION, 2021-2028 (USD MILLION)	127
9.17	OTHER APPLICATIONS	128
TABLE 51	CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)	128
10	CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER	129
10.1	INTRODUCTION	130
TABLE 52	CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	130
10.2	HOSPITALS	130
10.2.1	GROWING PATIENT POPULATION AND TESTING VOLUMES TO DRIVE MARKET	130
TABLE 53	CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR HOSPITALS, BY REGION, 2021-2028 (USD MILLION)	132
10.3	CLINICAL LABORATORIES	132
10.3.1	RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO DRIVE SEGMENT	132
TABLE 54	CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021-2028 (USD MILLION)	133
10.4	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS	134
10.4.1	RISING DRUG DISCOVERIES AND CLINICAL STUDIES TO DRIVE MARKET	134
TABLE 55	CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION)	135
10.5	OTHER END USERS	135
TABLE 56	CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)	136
11	CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION	137
11.1	INTRODUCTION	138
TABLE 57	CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021-2028 (USD MILLION)	138
11.2	NORTH AMERICA	139
FIGURE 38	NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT	140
TABLE 58	NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	141
TABLE 59	NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	141
TABLE 60	NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	142
TABLE 61	NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	142
TABLE 62	NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	143

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



TABLE 63 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION) 144

11.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA 144

11.2.2 US 145

11.2.2.1 US to hold largest share in North American chemiluminescence immunoassay market during forecast period 145

TABLE 64 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 145

TABLE 65 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 146

TABLE 66 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION) 146

TABLE 67 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 147

TABLE 68 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION) 148

11.2.3 CANADA 148

11.2.3.1 Rising government initiatives and funding for early disease diagnosis to drive market 148

TABLE 69 CANADA: ESTIMATED PREVALENCE OF DIABETES 148

TABLE 70 CANADA: MACROECONOMIC INDICATORS 150

TABLE 71 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 150

TABLE 72 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 151

TABLE 73 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION) 151

TABLE 74 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 152

TABLE 75 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION) 153

11.3 EUROPE 153

TABLE 76 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 154

TABLE 77 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 154

TABLE 78 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 155

TABLE 79 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION) 155

TABLE 80 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 156

TABLE 81 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION) 157

11.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE 157

11.3.2 GERMANY 157

11.3.2.1 Growing investments in clinical diagnostics research and increasing government spending on healthcare to drive market 157

TABLE 82 GERMANY: MACROECONOMIC INDICATORS 158

TABLE 83 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 159

TABLE 84 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 159

TABLE 85 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION) 160

TABLE 86 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 161

TABLE 87 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION) 162

11.3.3 FRANCE 162

11.3.3.1 Favorable reimbursement policies and increased investments in diagnostics to drive market 162

TABLE 88 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 163

TABLE 89 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 163

TABLE 90 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION) 164

TABLE 91 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 165

TABLE 92 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION) 166

11.3.4 UK 166

11.3.4.1 Increasing number of accredited clinical laboratories and growing accessibility to IVD tests to drive market 166

TABLE 93 UK: MACROECONOMIC INDICATORS 167

TABLE 94 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 168

TABLE 95 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 168

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 96	UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	169
TABLE 97	UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	170
TABLE 98	UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	171
11.3.5	ITALY	171
11.3.5.1	Growing geriatric population and increasing support for research to drive market	171
TABLE 99	ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	172
TABLE 100	ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	172
TABLE 101	ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	173
TABLE 102	ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	174
TABLE 103	ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	175
11.3.6	SPAIN	175
11.3.6.1	Rising adoption of technologically advanced immunoassay systems to drive market	175
TABLE 104	SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	176
TABLE 105	SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	176
TABLE 106	SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	177
TABLE 107	SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	178
TABLE 108	SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	179
11.3.7	REST OF EUROPE	179
TABLE 109	REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	180
TABLE 110	REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	180
TABLE 111	REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	181
TABLE 112	REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	182
TABLE 113	REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	183
11.4	ASIA PACIFIC	183
FIGURE 39	ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT	184
TABLE 114	ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	185
TABLE 115	ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	185
TABLE 116	ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	186
TABLE 117	ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	186
TABLE 118	ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	187
TABLE 119	ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	188
11.4.1	IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC	188
11.4.2	JAPAN	188
11.4.2.1	Growing investments in clinical diagnostics research to drive market	188
TABLE 120	JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	189
TABLE 121	JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	190
TABLE 122	JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	190
TABLE 123	JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	191
TABLE 124	JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	192
11.4.3	CHINA	192
11.4.3.1	China to register highest growth rate in Asia Pacific chemiluminescence immunoassay market during study period	192
TABLE 125	CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	193
TABLE 126	CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	194
TABLE 127	CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	194
TABLE 128	CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	195
TABLE 129	CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	196
11.4.4	INDIA	196

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.4.4.1	Growing medical tourism and healthcare infrastructure to drive market	196
TABLE 130	INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	197
TABLE 131	INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	198
TABLE 132	INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	198
TABLE 133	INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	199
TABLE 134	INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	200
11.4.5	SOUTH KOREA	200
11.4.5.1	Rising healthcare spending for innovative IVD technologies to drive market	200
TABLE 135	SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	201
TABLE 136	SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	201
TABLE 137	SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	202
TABLE 138	SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	203
TABLE 139	SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	204
11.4.6	REST OF ASIA PACIFIC	204
TABLE 140	REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	205
TABLE 141	REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	206
TABLE 142	REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	206
TABLE 143	REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	207
TABLE 144	REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	208
11.5	REST OF THE WORLD	208
TABLE 145	REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021-2028 (USD MILLION)	208
TABLE 146	REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	209
TABLE 147	REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	209
TABLE 148	REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	210
TABLE 149	REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	211
TABLE 150	REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	212
11.5.1	IMPACT OF ECONOMIC RECESSION ON REST OF THE WORLD	212
11.5.2	LATIN AMERICA	212
11.5.2.1	Rising incidence of infectious diseases and increasing geriatric population to drive market	212
TABLE 151	LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	213
TABLE 152	LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	214
TABLE 153	LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	214
TABLE 154	LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	215
TABLE 155	LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	216
11.5.3	MIDDLE EAST & AFRICA	216
11.5.3.1	Lack of skilled laboratory personnel and unfavorable reimbursement policies to limit market	216
TABLE 156	MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	217
TABLE 157	MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	217
TABLE 158	MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)	218
TABLE 159	MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	219
TABLE 160	MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)	220
12	COMPETITIVE LANDSCAPE	221
12.1	OVERVIEW	221
12.2	STRATEGIES ADOPTED BY KEY PLAYERS	221
TABLE 161	OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURERS OF CHEMILUMINESCENCE IMMUNOASSAY	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## PRODUCTS 222

### 12.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS 223

FIGURE 40 REVENUE ANALYSIS OF TOP MARKET PLAYERS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 223

### 12.4 MARKET SHARE ANALYSIS 224

TABLE 162 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEGREE OF COMPETITION 224

FIGURE 41 CHEMILUMINESCENCE IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022) 225

### 12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 226

#### 12.5.1 STARS 226

#### 12.5.2 EMERGING LEADERS 226

#### 12.5.3 PERVASIVE PLAYERS 226

#### 12.5.4 PARTICIPANTS 226

FIGURE 42 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS 227

### 12.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS 228

#### 12.6.1 PROGRESSIVE COMPANIES 228

#### 12.6.2 STARTING BLOCKS 228

#### 12.6.3 RESPONSIVE COMPANIES 228

#### 12.6.4 DYNAMIC COMPANIES 228

FIGURE 43 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES 229

### 12.7 COMPETITIVE BENCHMARKING 230

TABLE 163 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES 230

### 12.8 COMPANY FOOTPRINT ANALYSIS 231

TABLE 164 OVERALL COMPANY FOOTPRINT 231

TABLE 165 COMPANY PRODUCT FOOTPRINT 231

TABLE 166 COMPANY REGIONAL FOOTPRINT 232

### 12.9 COMPETITIVE SCENARIO 232

#### 12.9.1 KEY PRODUCT LAUNCHES AND APPROVALS 232

TABLE 167 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY PRODUCT LAUNCHES AND APPROVALS, 2020-2023 232

#### 12.9.2 KEY DEALS 234

TABLE 168 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY DEALS, 2020-2023 234

#### 12.9.3 OTHER KEY DEVELOPMENTS 234

TABLE 169 CHEMILUMINESCENCE IMMUNOASSAY MARKET: OTHER KEY DEVELOPMENTS, 2020-2023 234

?

## 13 COMPANY PROFILES 236

### 13.1 KEY PLAYERS 236

(Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win)\*

#### 13.1.1 F. HOFFMANN-LA ROCHE LTD. 236

TABLE 170 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 236

FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 237

#### 13.1.2 DANAHER CORPORATION 239

TABLE 171 DANAHER CORPORATION: COMPANY OVERVIEW 239

FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 240

#### 13.1.3 SIEMENS HEALTHINEERS AG 242

TABLE 172 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 242

FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 243

#### 13.1.4 DIASORIN S.P.A. 246

TABLE 173 DIASORIN S.P.A.: COMPANY OVERVIEW 246

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 47	DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)	247
13.1.5	ABBOTT LABORATORIES	248
TABLE 174	ABBOTT LABORATORIES: COMPANY OVERVIEW	248
FIGURE 48	ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)	249
13.1.6	SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	251
TABLE 175	SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW	251
FIGURE 49	SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2021)	252
13.1.7	SYSMEX CORPORATION	254
TABLE 176	SYSMEX CORPORATION: COMPANY OVERVIEW	254
FIGURE 50	SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)	255
13.1.8	DIATRON	258
TABLE 177	DIATRON: COMPANY OVERVIEW	258
FIGURE 51	STRATEC SE: COMPANY SNAPSHOT (2022)	259
13.1.9	GETEIN BIOTECH, INC.	260
TABLE 178	GETEIN BIOTECH, INC.: COMPANY OVERVIEW	260
13.1.10	WERFEN	261
TABLE 179	WERFEN: COMPANY OVERVIEW	261
13.1.11	QUIDELORTHO CORPORATION	262
TABLE 180	QUIDELORTHO CORPORATION: COMPANY OVERVIEW	262
FIGURE 52	QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)	263
13.1.12	EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG	265
TABLE 181	EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY OVERVIEW	265
*Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win might not be captured in case of unlisted companies.		
13.2	OTHER PLAYERS	267
13.2.1	MERCK KGAA	267
13.2.2	TOSOH CORPORATION (TOSOH BIOSCIENCE)	267
13.2.3	TRIVITRON HEALTHCARE	268
13.2.4	ABNOVA CORPORATION	268
13.2.5	ELABSCIENCE	269
13.2.6	MACCURA BIOTECHNOLOGY CO., LTD.	269
13.2.7	AUTOBIO DIAGNOSTICS CO., LTD	270
13.2.8	JIANGSU ZECEN BIOTECH CO., LTD	270
13.2.9	RAYTO LIFE AND ANALYTICAL SCIENCES CO., LTD.	271
13.2.10	DAAN GENE CO., LTD.	272
13.2.11	DYNEX TECHNOLOGIES, INC.	272
13.2.12	ZYBIO INC.	273
13.2.13	WIENER LABORATORIOS SAIC	273
13.2.14	TIANJIN ERA BIOLOGY TECHNOLOGY CO., LTD.	274
14	APPENDIX	275
14.1	DISCUSSION GUIDE	275
14.2	KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL	279
14.3	CUSTOMIZATION OPTIONS	281
14.4	RELATED REPORTS	282
14.5	AUTHOR DETAILS	283

**Chemiluminescence Immunoassay Market by Product (Instrument, Consumable),  
Technology (Chemiluminescence Enzyme, Microparticle Chemiluminescence), Sample  
(Blood, Urine), Application (Infectious Disease, Oncology), End User - Global Forecast  
to 2028**

Market Report | 2023-07-05 | 276 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code\*

Country\*

Date

Signature